GAA and central nervous system cancer: In the context of glioma vaccines, Prins et al. have compared the safety, feasibility, and immune responses of two DC vaccine formats; autologous tumor-lysate (ATL)-pulsed DCs and glioma-associated antigen (GAA) peptide-pulsed DCs [146].